Designed with the Vaginal Microbiome in Mind

A healthy vaginal microbiome depends on a balanced microbial community, or state of symbiosis, that includes beneficial bacteria—particularly Lactobacillus species such as L. crispatus. Disruption of this balance, or dysbiosis, is associated with vaginal conditions such as bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC).

Cern’s microbicidal-light treatment is being developed to reduce disease-associated bacterial and fungal pathogens while supporting preservation of beneficial vaginal bacteria. Because the antimicrobial effect is dependent on treatment parameters, including light dose and exposure duration, the technology may provide an opportunity to establish a therapeutic window that effectively reduces targeted pathogens while minimizing effects on beneficial organisms.

Cern’s laboratory testing suggests that key beneficial bacteria such as L. crispatus may demonstrate greater resilience to certain treatment conditions than disease-associated pathogens. This is particularly relevant because Lactobacillus-dominant vaginal communities, including those dominated by L. crispatus, are generally associated with vaginal health, while their depletion is frequently associated with vaginal dysbiosis.

This potential differential response may allow Cern’s treatment parameters to be optimized to reduce pathogenic microbial burden while limiting disruption of beneficial vaginal flora—an important consideration for women experiencing recurrent vaginal infections.

Rather than simply treating an infection, Cern’s approach is being developed with the broader vaginal microbial ecosystem in mind, with the goal of treating disease while supporting the conditions associated with a healthy, balanced vaginal microbiome.